Commercial expansion ClearNote Health is actively expanding commercialization of its blood-based cancer detection platform, supported by a $52M Series D and leadership additions. This presents opportunities to engage payors, labs, and contract research organizations to scale adoption, integration, and reimbursement efforts.

Payor network Partnerships with Claritev to expose Avantect tests to 700+ payors and 1.4M providers indicate a strong channel for market access. Sales roles can target payer relations, hospital networks, and provider groups to accelerate coverage and in-network adoption.

Clinical validation Ongoing multi-cohort validation and presentations at ASCO and DDW signal robust clinical evidence generation. This supports selling points around test accuracy, early detection value, and monitoring capabilities to clinicians, health systems, and informatics teams.

Laboratory readiness With CLIA and CAP accreditation and a San Diego lab plus Bay Area presence, ClearNote Health offers scalable, compliant testing operations. Opportunities exist to upsell laboratory services, analytics integrations, and data-sharing arrangements with hospital systems and reference labs.

Technology moat The Virtuoso epigenomics platform combining 5hmC signatures and AI-driven analysis positions ClearNote Health as a differentiated provider. Sales efforts can emphasize technology advantages to pharma, clinicians, and payer groups seeking innovative monitoring and treatment-response tools.